<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD06860000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P11362</UniProt_ID>
  <Seq_Length>822</Seq_Length>
  <Molecule_Weight>91868</Molecule_Weight>
  <KEGG_ID>hsa:2260</KEGG_ID>
  <Orthology_ID>K04362</Orthology_ID>
  <EBI_ID>EBI-1028277</EBI_ID>
  <Function_Summary>Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF07679:I-set@@PF07714:Pkinase_Tyr</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>N-sam</Alias>
      <Alias>BFGFR</Alias>
      <Alias>Basic fibroblast growth factor receptor 1</Alias>
      <Alias>Fms-like tyrosine kinase 2</Alias>
      <Alias>FLT-2</Alias>
      <Alias>bFGF-R-1</Alias>
      <Alias>FGFR-1</Alias>
      <Alias>Proto-oncogene c-Fgr</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with fibroblast growth factor.</Detail>
      <Keyword>Fibroblast growth factor binding</Keyword>
      <Ontology_ID>GO:0017134</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heparin, any member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha1-4-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.</Detail>
      <Keyword>Heparin binding</Keyword>
      <Ontology_ID>GO:0008201</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with fibroblast growth factor to initiate a change in cell activity.</Detail>
      <Keyword>Fibroblast growth factor receptor activity</Keyword>
      <Ontology_ID>GO:0005007</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>346</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>772</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>769</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>687</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>277</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>129</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>77</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>224</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>254</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>283</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>607</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>213</Position>
      <Original>Trp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>622</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>724</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>97</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>622</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>237</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>666</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>78</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>538</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>237</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>270</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>664</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>703</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>374</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>300</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>520</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>339</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>101</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>330</Position>
      <Original>Asn</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>822</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>693</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>178</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>722</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>685</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>48</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>818</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>250</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>332</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>621</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>245</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>795</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>381</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>703</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>274</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>273</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>99</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>366</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>722</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>719</Position>
      <Original>Met</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>125</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>745</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>167</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>22</Position>
      <Original>Arg</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>102</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A series of molecular signals in which a cell uses a phosphatidylinositol-mediated signaling to convert a signal into a response. Phosphatidylinositols include phosphatidylinositol (PtdIns) and its phosphorylated derivatives.</Detail>
      <Keyword>Phosphatidylinositol-mediated signaling</Keyword>
      <Ontology_ID>GO:0048015</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which the anatomical structures of the skeleton are generated and organized.</Detail>
      <Keyword>Skeletal system morphogenesis</Keyword>
      <Ontology_ID>GO:0048705</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemotaxis process that directs the migration of an axon growth cone to a specific target site in response to a combination of attractive and repulsive cues.</Detail>
      <Keyword>Axon guidance</Keyword>
      <Ontology_ID>GO:0007411</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of neuron differentiation.</Detail>
      <Keyword>Positive regulation of neuron differentiation</Keyword>
      <Ontology_ID>GO:0045666</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade.</Detail>
      <Keyword>Positive regulation of phosphatidylinositol 3-kinase cascade</Keyword>
      <Ontology_ID>GO:0014068</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The characteristic movement of an immature neuron from germinal zones to specific positions where they will reside as they mature.</Detail>
      <Keyword>Neuron migration</Keyword>
      <Ontology_ID>GO:0001764</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of at least three protein kinase activities culminating in the phosphorylation and activation of a MAP kinase. MAPKKK cascades lie downstream of numerous signaling pathways.</Detail>
      <Keyword>MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0000165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.</Detail>
      <Keyword>Positive regulation of MAPKKK cascade</Keyword>
      <Ontology_ID>GO:0043410</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate of phospholipase C activity.</Detail>
      <Keyword>Positive regulation of phospholipase C activity</Keyword>
      <Ontology_ID>GO:0010863</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of MAP kinase activity.</Detail>
      <Keyword>Positive regulation of MAP kinase activity</Keyword>
      <Ontology_ID>GO:0043406</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation of peptidyl-tyrosine to form peptidyl-O4'-phospho-L-tyrosine.</Detail>
      <Keyword>Peptidyl-tyrosine phosphorylation</Keyword>
      <Ontology_ID>GO:0018108</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of the insulin receptor binding to insulin.</Detail>
      <Keyword>Insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0008286</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The phosphorylation by a protein of one or more of its own amino acid residues, or residues on an identical protein.</Detail>
      <Keyword>Protein autophosphorylation</Keyword>
      <Ontology_ID>GO:0046777</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>654</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>730</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>766</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>585</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>583</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>463</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>653</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR</Protein_Seq>
    <DNA_Seq>AGATGCAGGGGCGCAAACGCCAAAGGAGACCAGGCTGTAGGAAGAGAAGGGCAGAGCGCCGGACAGCTCGGCCCGCTCCCCGTCCTTTGGGGCCGCGGCTGGGGAACTACAAGGCCCAGCAGGCAGCTGCAGGGGGCGGAGGCGGAGGAGGGACCAGCGCGGGTGGGAGTGAGAGAGCGAGCCCTCGCGCCCCGCCGGCGCATAGCGCTCGGAGCGCTCTTGCGGCCACAGGCGCGGCGTCCTCGGCGGCGGGCGGCAGCTAGCGGGAGCCGGGACGCCGGTGCAGCCGCAGCGCGCGGAGGAACCCGGGTGTGCCGGGAGCTGGGCGGCCACGTCCGGACGGGACCGAGACCCCTCGTAGCGCATTGCGGCGACCTCGCCTTCCCCGGCCGCGAGCGCGCCGCTGCTTGAAAAGCCGCGGAACCCAAGGACTTTTCTCCGGTCCGAGCTCGGGGCGCCCCGCAGGGCGCACGGTACCCGTGCTGCAGTCGGGCACGCCGCGGCGCCGGGGCCTCCGCAGGGCGATGGAGCCCGGTCTGCAAGGAAAGTGAGGCGCCGCCGCTGCGTTCTGGAGGAGGGGGGCACAAGGTCTGGAGACCCCGGGTGGCGGACGGGAGCCCTCCCCCCGCCCCGCCTCCGGGGCACCAGCTCCGGCTCCATTGTTCCCGCCCGGGCTGGAGGCGCCGAGCACCGAGCGCCGCCGGGAGTCGAGCGCCGGCCGCGGAGCTCTTGCGACCCCGCCAGGACCCGAACAGAGCCCGGGGGCGGCGGGCCGGAGCCGGGGACGCGGGCACACGCCCGCTCGCACAAGCCACGGCGGACTCTCCCGAGGCGGAACCTCCACGCCGAGCGAGGGTCAGTTTGAAAAGGAGGATCGAGCTCACTGTGGAGTATCCATGGAGATGTGGAGCCTTGTCACCAACCTCTAACTGCAGAACTGGGATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACCGCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGATGTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGCATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCTTGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGATGCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAAACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAGATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCCAGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGACCACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTGGTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAACCACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGGTTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTACAGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATTGGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGACAAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACGTGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAAGCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTATTGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAGAGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGCATCCCTCTGCGCAGACAGGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTTCTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAGTATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTAGGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTGGACAAGGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCAACAGAGAAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAGCATAAGAATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATCGTGGAGTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGGCTGGAATACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTGGTGTCCTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATACACCGAGACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCAGACTTTGGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGATGTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCCGGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCCAGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCACAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGACCTCCAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTTCCCGACACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGCTGCCCGAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGCTGACTGCCACCCACACGCCCTCCCCAGACTCCACCGTCAGCTGTAACCCTCACCCACAGCCCCTGCTGGGCCCACCACCTGTCCGTCCCTGTCCCCTTTCCTGCTGGCAGGAGCCGGCTGCCTACCAGGGGCCTTCCTGTGTGGCCTGCCTTCACCCCACTCAGCTCACCTCTCCCTCCACCTCCTCTCCACCTGCTGGTGAGAGGTGCAAAGAGGCAGATCTTTGCTGCCAGCCACTTCATCCCCTCCCAGATGTTGGACCAACACCCCTCCCTGCCACCAGGCACTGCCTGGAGGGCAGGGAGTGGGAGCCAATGAACAGGCATGCAAGTGAGAGCTTCCTGAGCTTTCTCCTGTCGGTTTGGTCTGTTTTGCCTTCACCCATAAGCCCCTCGCACTCTGGTGGCAGGTGCCTTGTCCTCAGGGCTACAGCAGTAGGGAGGTCAGTGCTTCGTGCCTCGATTGAAGGTGACCTCTGCCCCAGATAGGTGGTGCCAGTGGCTTATTAATTCCGATACTAGTTTGCTTTGCTGACCAAATGCCTGGTACCAGAGGATGGTGAGGCGAAGGCCAGGTTGGGGGCAGTGTTGTGGCCCTGGGGCCCAGCCCCAAACTGGGGGCTCTGTATATAGCTATGAAGAAAACACAAAGTGTATAAATCTGAGTATATATTTACATGTCTTTTTAAAAGGGTCGTTACCAGAGATTTACCCATCGGGTAAGATGCTCCTGGTGGCTGGGAGGCATCAGTTGCTATATATTAAAAACAAAAAAGAAAAAAAAGGAAAATGTTTTTAAAAAGGTCATATATTTTTTGCTACTTTTGCTGTTTTATTTTTTTAAATTATGTTCTAAACCTATTTTCAGTTTAGGTCCCTCAATAAAAATTGCTGCTGCTTCATTTATCTATGGGCTGTATGAAAAGGGTGGGAATGTCCACTGGAAAGAAGGGACACCCACGGGCCCTGGGGCTAGGTCTGTCCCGAGGGCACCGCATGCTCCCGGCGCAGGTTCCTTGTAACCTCTTCTTCCTAGGTCCTGCACCCAGACCTCACGACGCACCTCCTGCCTCTCCGCTGCTTTTGGAAAGTCAGAAAAAGAAGATGTCTGCTTCGAGGGCAGGAACCCCATCCATGCAGTAGAGGCGCTGGGCAGAGAGTCAAGGCCCAGCAGCCATCGACCATGGATGGTTTCCTCCAAGGAAACCGGTGGGGTTGGGCTGGGGAGGGGGCACCTACCTAGGAATAGCCACGGGGTAGAGCTACAGTGATTAAGAGGAAAGCAAGGGCGCGGTTGCTCACGCCTGTAATCCCAGCACTTTGGGACACCGAGGTGGGCAGATCACTTCAGGTCAGGAGTTTGAGACCAGCCTGGCCAACTTAGTGAAACCCCATCTCTACTAAAAATGCAAAAATTATCCAGGCATGGTGGCACACGCCTGTAATCCCAGCTCCACAGGAGGCTGAGGCAGAATCCCTTGAAGCTGGGAGGCGGAGGTTGCAGTGAGCCGAGATTGCGCCATTGCACTCCAGCCTGGGCAACAGAGAAAACAAAAAGGAAAACAAATGATGAAGGTCTGCAGAAACTGAAACCCAGACATGTGTCTGCCCCCTCTATGTGGGCATGGTTTTGCCAGTGCTTCTAAGTGCAGGAGAACATGTCACCTGAGGCTAGTTTTGCATTCAGGTCCCTGGCTTCGTTTCTTGTTGGTATGCCTCCCCAGATCGTCCTTCCTGTATCCATGTGACCAGACTGTATTTGTTGGGACTGTCGCAGATCTTGGCTTCTTACAGTTCTTCCTGTCCAAACTCCATCCTGTCCCTCAGGAACGGGGGGAAAATTCTCCGAATGTTTTTGGTTTTTTGGCTGCTTGGAATTTACTTCTGCCACCTGCTGGTCATCACTGTCCTCACTAAGTGGATTCTGGCTCCCCCGTACCTCATGGCTCAAACTACCACTCCTCAGTCGCTATATTAAAGCTTATATTTTGCTGGATTACTGCTAAATACAAAAGAAAGTTCAATATGTTTTCATTTCTGTAGGGAAAATGGGATTGCTGCTTTAAATTTCTGAGCTAGGGATTTTTTGGCAGCTGCAGTGTTGGCGACTATTGTAAAATTCTCTTTGTTTCTCTCTGTAAATAGCACCTGCTAACATTACAATTTGTATTTATGTTTAAAGAAGGCATCATTTGGTGAACAGAACTAGGAAATGAATTTTTAGCTCTTAAAAGCATTTGCTTTGAGACCGCACAGGAGTGTCTTTCCTTGTAAAACAGTGATGATAATTTCTGCCTTGGCCCTACCTTGAAGCAATGTTGTGTGAAGGGATGAAGAATCTAAAAGTCTTCATAAGTCCTTGGGAGAGGTGCTAGAAAAATATAAGGCACTATCATAATTACAGTGATGTCCTTGCTGTTACTACTCAAATCACCCACAAATTTCCCCAAAGACTGCGCTAGCTGTCAAATAAAAGACAGTGAAATTGACCTGA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Foreskin fibroblast cell lines</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Neuroblastoma</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Adrenal cortex cell lines</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Astrocytoma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to plasma membrane</CellLocal>
      <Ontology_ID>GO:0005887</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasmic vesicle</CellLocal>
      <Ontology_ID>GO:0031410</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasmic membrane-bounded vesicle</CellLocal>
      <Ontology_ID>GO:0016023</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>FGFR1</Gene_Name>
    <Gene_Alias>BFGFR; CEK; FGFBR; FLG; FLT2; HBGFR</Gene_Alias>
    <Gene_ID>2260</Gene_ID>
    <Genbank_ACCN>NM_001174063</Genbank_ACCN>
    <Protein_ACCN>NP_001167534</Protein_ACCN>
    <HGNC_ID>3688</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2260</Gene_URL>
    <UCSC_ID>uc022aud.1</UCSC_ID>
    <EMBL_ID>ENSG00000077782</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P12830</Uniprot_ID>
      <Gene_Name>CDH1</Gene_Name>
      <EBI_ID>EBI-727477</EBI_ID>
      <PPI_EBI_URL>EBI-1028277,EBI-727477</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P10686</Uniprot_ID>
      <Gene_Name>Plcg1</Gene_Name>
      <EBI_ID>EBI-520788</EBI_ID>
      <PPI_EBI_URL>EBI-1028277,EBI-520788</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P09038</Uniprot_ID>
      <Gene_Name>FGF2</Gene_Name>
      <EBI_ID>EBI-977447</EBI_ID>
      <PPI_EBI_URL>EBI-1028277,EBI-977447</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Fgfr-Related Craniosynostosis Syndromes</Disease_Name>
      <Disease_Detail>Fgfr-Related Craniosynostosis Syndromes</Disease_Detail>
      <Disease_DB>FGF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr_related_craniosynostosis_syndromes?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kallmann Syndrome 2</Disease_Name>
      <Disease_Detail>Kallmann Syndrome</Disease_Detail>
      <Disease_DB>KLL004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kallmann_syndrome_2?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Trigonocephaly, Nonsyndromic</Disease_Name>
      <Disease_Detail>Trigonocephaly</Disease_Detail>
      <Disease_DB>TRG011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/trigonocephaly_nonsyndromic?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Achondroplasia</Disease_Name>
      <Disease_Detail>Achondroplasia</Disease_Detail>
      <Disease_DB>ACH004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/achondroplasia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoglophonic Dysplasia</Disease_Name>
      <Disease_Detail>Osteoglophonic Dysplasia</Disease_Detail>
      <Disease_DB>OST044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoglophonic_dysplasia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acrocephalosyndactylia</Disease_Name>
      <Disease_Detail>Acrocephalosyndactylia</Disease_Detail>
      <Disease_DB>ACR015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acrocephalosyndactylia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gliosarcoma</Disease_Name>
      <Disease_Detail>Gliosarcoma</Disease_Detail>
      <Disease_DB>GLS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliosarcoma?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lobular Neoplasia</Disease_Name>
      <Disease_Detail>Lobular Neoplasia</Disease_Detail>
      <Disease_DB>LBL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lobular_neoplasia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Infectious Mononucleosis</Disease_Name>
      <Disease_Detail>Infectious Mononucleosis</Disease_Detail>
      <Disease_DB>INF030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/infectious_mononucleosis?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Septo-Optic Dysplasia</Disease_Name>
      <Disease_Detail>Septo-Optic Dysplasia</Disease_Detail>
      <Disease_DB>SPT014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/septo_optic_dysplasia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Radioulnar Synostosis</Disease_Name>
      <Disease_Detail>Radioulnar Synostosis</Disease_Detail>
      <Disease_DB>RDL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/radioulnar_synostosis?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr1-Related Craniosynostosis</Disease_Name>
      <Disease_Detail>Fgfr1-Related Craniosynostosis</Disease_Detail>
      <Disease_DB>FGF003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr1_related_craniosynostosis?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Saethre-Chotzen Syndrome</Disease_Name>
      <Disease_Detail>Saethre-Chotzen Syndrome</Disease_Detail>
      <Disease_DB>STH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/saethre_chotzen_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gliomatosis Cerebri</Disease_Name>
      <Disease_Detail>Gliomatosis Cerebri</Disease_Detail>
      <Disease_DB>GLM004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliomatosis_cerebri?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Synostosis</Disease_Name>
      <Disease_Detail>Synostosis</Disease_Detail>
      <Disease_DB>SYN005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/synostosis?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Muenke Syndrome</Disease_Name>
      <Disease_Detail>Muenke Syndrome</Disease_Detail>
      <Disease_DB>MNK003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/muenke_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Craniosynostosis</Disease_Name>
      <Disease_Detail>Craniosynostosis</Disease_Detail>
      <Disease_DB>CRN037</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/craniosynostosis?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteochondroma</Disease_Name>
      <Disease_Detail>Osteochondroma</Disease_Detail>
      <Disease_DB>OST028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteochondroma?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Antley-Bixler Syndrome</Disease_Name>
      <Disease_Detail>Antley-Bixler Syndrome</Disease_Detail>
      <Disease_DB>ANT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/antley_bixler_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypochondroplasia</Disease_Name>
      <Disease_Detail>Hypochondroplasia</Disease_Detail>
      <Disease_DB>HYP042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypochondroplasia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypogonadotropic Hypogonadism 2 with or Without Anosmia</Disease_Name>
      <Disease_Detail>Hypogonadotropic Hypogonadism</Disease_Detail>
      <Disease_DB>HYP548</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypogonadotropic_hypogonadism_2_with_or_without_anosmia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Giant Cell Glioblastoma</Disease_Name>
      <Disease_Detail>Giant Cell Glioblastoma</Disease_Detail>
      <Disease_DB>GNT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/giant_cell_glioblastoma?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tooth Agenesis, Selective, 1, with or Without Orofacial Cleft</Disease_Name>
      <Disease_Detail>Tooth Agenesis, Selective, 1, with or Without Orofacial Cleft</Disease_Detail>
      <Disease_DB>TTH016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tooth_agenesis_selective_1_with_or_without_orofacial_cleft?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypogonadotropic Hypogonadism 14 with or Without Anosmia</Disease_Name>
      <Disease_Detail>Hypogonadotropic Hypogonadism</Disease_Detail>
      <Disease_DB>HYP523</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypogonadotropic_hypogonadism_14_with_or_without_anosmia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pfeiffer Syndrome Type 1</Disease_Name>
      <Disease_Detail>Pfeiffer Syndrome</Disease_Detail>
      <Disease_DB>PFF007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pfeiffer_syndrome_type_1?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kallmann Syndrome</Disease_Name>
      <Disease_Detail>Kallmann Syndrome</Disease_Detail>
      <Disease_DB>KLL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kallmann_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Crouzon Syndrome</Disease_Name>
      <Disease_Detail>Crouzon Syndrome</Disease_Detail>
      <Disease_DB>CRZ001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/crouzon_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Jackson-Weiss Syndrome</Disease_Name>
      <Disease_Detail>Jackson-Weiss Syndrome</Disease_Detail>
      <Disease_DB>JCK001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/jackson_weiss_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Trigonocephaly 1</Disease_Name>
      <Disease_Detail>Trigonocephaly</Disease_Detail>
      <Disease_DB>TRG016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/trigonocephaly_1?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kallmann Syndrome 1</Disease_Name>
      <Disease_Detail>Kallmann Syndrome</Disease_Detail>
      <Disease_DB>KLL003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kallmann_syndrome_1?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>8p11 Myeloproliferative Syndrome</Disease_Name>
      <Disease_Detail>8p11 Myeloproliferative Syndrome</Disease_Detail>
      <Disease_DB>8P1002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/8p11_myeloproliferative_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myeloid Neoplasm Associated with Fgfr1 Rearrangement</Disease_Name>
      <Disease_Detail>Acute Myeloid Leukemia</Disease_Detail>
      <Disease_DB>MYL041</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myeloid_neoplasm_associated_with_fgfr1_rearrangement?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hartsfield Syndrome</Disease_Name>
      <Disease_Detail>Hartsfield Syndrome</Disease_Detail>
      <Disease_DB>HRT030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hartsfield_syndrome?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Salivary Gland Tumor</Disease_Name>
      <Disease_Detail>Salivary Gland Tumor</Disease_Detail>
      <Disease_DB>SLV021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/salivary_gland_tumor?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pilocytic Astrocytoma</Disease_Name>
      <Disease_Detail>Pilocytic Astrocytoma</Disease_Detail>
      <Disease_DB>PLC011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pilocytic_astrocytoma?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Cancer</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_cancer?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Plagiocephaly</Disease_Name>
      <Disease_Detail>Plagiocephaly</Disease_Detail>
      <Disease_DB>PLG004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/plagiocephaly?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fgfr1-Related Isolated Gonadotropin-Releasing Hormone   Deficiency</Disease_Name>
      <Disease_Detail>Fgfr1-Related Isolated Gonadotropin-Releasing Hormone   Deficiency</Disease_Detail>
      <Disease_DB>FGF011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fgfr1_related_isolated_gonadotropin_releasing_hormone_deficiency?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cleft Lip</Disease_Name>
      <Disease_Detail>Cleft Lip</Disease_Detail>
      <Disease_DB>CLF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cleft_lip?search=FGFR1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypogonadotropic Hypogonadism 9 with or Without Anosmia</Disease_Name>
      <Disease_Detail>Hypogonadotropic Hypogonadism</Disease_Detail>
      <Disease_DB>HYP444</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypogonadotropic_hypogonadism_9_with_or_without_anosmia?search=FGFR1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX</PDB_Title>
      <PDB_ID>1FQ9</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FQ9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.</PubMed_Title>
      <Author>Schlessinger, J., et al.</Author>
      <Journal>Mol.Cell(2000)6:743-750</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11030354?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of the mutant Fibroblast Growth Factor receptor 1</PDB_Title>
      <PDB_ID>3KXX</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KXX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.</PubMed_Title>
      <Author>Bae, J.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:2866-2871</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133753?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domain</PDB_Title>
      <PDB_ID>3KY2</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KY2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells.</PubMed_Title>
      <Author>Bae, J.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:2866-2871</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20133753?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5-(2-thienyl)nicotinic acid</PDB_Title>
      <PDB_ID>3JS2</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3JS2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening</PubMed_Title>
      <Author>Ravindranathan, K.P., et al.</Author>
      <Journal>J.Med.Chem.(2010)53:1662-1672</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20121196?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1</PDB_Title>
      <PDB_ID>2CR3</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2CR3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074</PDB_Title>
      <PDB_ID>2FGI</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FGI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.</PubMed_Title>
      <Author>Mohammadi, M., et al.</Author>
      <Journal>EMBO J.(1998)17:5896-5904</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9774334?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-piperidin-4-yl-phenyl)-amide</PDB_Title>
      <PDB_ID>3KRJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KRJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).</PubMed_Title>
      <Author>Illig, C.R., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:7860-7883</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22039836?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX</PDB_Title>
      <PDB_ID>1CVS</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1CVS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for FGF receptor dimerization and activation.</PubMed_Title>
      <Author>Plotnikov, A.N., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(1999)98:641-650</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10490103?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors</PDB_Title>
      <PDB_ID>1XR0</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XR0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors</PubMed_Title>
      <Author>Dhalluin, C., et al.</Author>
      <Journal>Mol.Cell(2000)6:921-929</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11090629?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of activated receptor tyrosine kinase in complex with substrates</PDB_Title>
      <PDB_ID>3GQI</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GQI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.</PubMed_Title>
      <Author>Bae, J.H., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(2009)138:514-524</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19665973?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindole</PDB_Title>
      <PDB_ID>3C4F</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3C4F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</PubMed_Title>
      <Author>Tsai, J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:3041-3046</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18287029?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069</PDB_Title>
      <PDB_ID>3RHX</PDB_ID>
      <Resolution>2.01</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RHX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.</PubMed_Title>
      <Author>Eathiraj, S., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:20677-20687</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21454610?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR</PDB_Title>
      <PDB_ID>1FGI</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FGI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.</PubMed_Title>
      <Author>Mohammadi, M., et al.</Author>
      <Journal>Science(1997)276:955-960</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9139660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR</PDB_Title>
      <PDB_ID>1AGW</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AGW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.</PubMed_Title>
      <Author>Mohammadi, M., et al.</Author>
      <Journal>Science(1997)276:955-960</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9139660?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1</PDB_Title>
      <PDB_ID>1FGK</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FGK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism.</PubMed_Title>
      <Author>Mohammadi, M., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(1996)86:577-587</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8752212?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of FGF1 complexed with the ectodomain of FGFR1c exhibiting an ordered ligand specificity-determining betaC'-betaE loop</PDB_Title>
      <PDB_ID>3OJV</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OJV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Plasticity in Interactions of Fibroblast Growth Factor 1 (FGF1) N Terminus with FGF Receptors Underlies Promiscuity of FGF1.</PubMed_Title>
      <Author>Beenken, A., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:3067-3078</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22057274?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of activated receptor tyrosine kinase in complex with substrates</PDB_Title>
      <PDB_ID>3GQL</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GQL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site.</PubMed_Title>
      <Author>Bae, J.H., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(2009)138:514-524</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19665973?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1)</PDB_Title>
      <PDB_ID>1EVT</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1EVT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.</PubMed_Title>
      <Author>Plotnikov, A.N., et al.</Author>
      <Journal>Cell(Cambridge,Mass.)(2000)101:413-424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10830168?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2-piperidin-1-yl-phenyl]-amide</PDB_Title>
      <PDB_ID>3KRL</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KRL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Optimization of a Potent Class of Arylamide Colony-Stimulating Factor-1 Receptor Inhibitors Leading to Anti-inflammatory Clinical Candidate 4-Cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).</PubMed_Title>
      <Author>Illig, C.R., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:7860-7883</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22039836?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04520</Pathway_ID>
      <Pathway_Title>Adherens junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://www.cathdb.info/pdb/1agw</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1agw</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.1</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/1.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>